Non-invasive ocular RNAi delivery

Article

RXi and EyeGate have announced a collaboration focused on non-invasive ocular delivery of RNAi therapeutics. Both companies will contribute technology, expertise and resources to the partnership.

RXi and EyeGate have announced a collaboration focused on non-invasive ocular delivery of RNAi therapeutics. Both companies will contribute technology, expertise and resources to the partnership.

The companies will explore the use of EyeGate's iontophoresis technology to deliver RXi's sd-rxRNA compounds to the eye in preclinical models. Iontophoresis technology is a method of drug delivery that uses a low-level electrical current to deliver a drug across the ocular surface into the eye. Once in the eye it is believed that the sd-rxRNA compounds will enter the retinal cells and silence disease causing genes.

President and CEO of RXi, Noah D. Beerman, explained: "In pre-clinical studies, our sd-rxRNA (or self-delivering rxRNA) compounds have shown effective gene silencing in the retina following intraocular injection. Combining our RNAi technology with EyeGate's unique, non-invasive ocular delivery system (EyeGate II), provides us with the potential opportunity to develop novel treatments for many ocular diseases and to improve treatment options."

Stephen From, president and CEO of EyeGate Pharma, added: "Our collaboration with RXi will enable us to expand the drug delivery options for the EyeGate II delivery system into RNAi therapeutics, developing new uses and markets for the device…"

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.